Clinical trials: HPV Infection
Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
- Trial name
- NCT06632912
- Testing
- 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
HPV Infection, HPV Vaccine
Intradermal, Fractional Dose of HPV Vaccines:
This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington.
- Trial name
- NCT04235257
- Testing
- HPV vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Washington
Infections, Papillomavirus
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years.
- Trial name
- NCT00996125
- Testing
- CervarixTM, Control
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Warts
Nanopulse Efficacy Study for the Treatment of Common Warts
The purpose of this study is to determine if the Nanopulse System can be used to clear common wart lesions on the skin. The Nanopulse System uses a series of low energy, high voltage pulses, each one several billionths of a…
- Trial name
- NCT02650466
- Testing
- Nanopulse System
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Human Papillomavirus Infection, Self Sampling
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc. developed a safe and comfortable vaginal self-sampling device "Hygeia Touch Self Sampling Kit for Women" to self-collect the vaginal discharge sample for high-risk Human Papillomavirus (hrHPV) detection.
- Conditions
- Human Papillomavirus Infection, Self Sampling, Vaginal Discharge
- Trial name
- NCT04472377
- Testing
- Self sampling kit for collecting discharge from vaginal fornix
- Where
- 3 sites in Taiwan
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Hygeia Touch Inc.
Game-Based Learning, Educational Intervention
Gamified Learning Methods and HPV Knowledge in Nursing Students
This study is a randomized controlled trial (RCT) with a pretest-posttest-follow-up design that compares the effectiveness of gamified teaching methods (Gimkit and educational escape room) with traditional theoretical education…
- Conditions
- Game-Based Learning, Educational Intervention, Nursing Education
- Trial name
- NCT07557719
- Testing
- Gimkit-Based Game-Based Learning, Escape Room-Based Game-Based Learning
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
HPV Infections
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen of Gardasil administered to healthy married females between 16 and 23 years of age, in India.
- Trial name
- NCT00733122
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vaginal Infection, ASC-US
Probiotic Implementation as Help in Solving Vaginal Infections
Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women's well-being.
- Trial name
- NCT03372395
- Testing
- Lactobacillus rhamnosus BMX 54
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cervical Intraepithelial Neoplasia, Human Papillomavirus Infection
HPV Genotyping by DR. HPV Genotyping in Vitro Diagnostic Device (IVD) Kit in Exfoliated Cells of the Uterine Cervix
High-risk type human papillomavirus (HPV) is the known etiological agent of cervical cancer. HPV testing and risk stratification by genotyping has been recognized as an effective cervical screening program.
- Conditions
- Cervical Intraepithelial Neoplasia, Human Papillomavirus Infection, HPV Infection
- Trial name
- NCT04333212
- Testing
- DR. Chip HPV genotyping IVD kit
- Where
- 4 sites in Taiwan
- Volunteers
- 1,103 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Cervical Cancer
Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra
The study goals are, 1. To determine the test characteristics (sensitivity, specificity, positive predictive value, negative predictive value, false positivity rates, false negativity rates) of health personnel collected and self…
- Trial name
- HPV (NCT03386695)
- Testing
- Education by Pamphlets, Health education programme
- Where
- India
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
HPV Infection
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years
- Trial name
- NCT07281677
- Testing
- bivalent HPV vaccine, 9-valent HPV vaccine
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Dose Schedule Study
Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
To demonstrate that Gardasil® vaccine, when given to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months), results in anti-HPV type 16 and anti-HPV type…
- Trial name
- NCT00524745
- Testing
- Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Where
- Vietnam
- Volunteers
- 903 people, healthy volunteers welcome
- Sponsor
- PATH
Anal Intraepithelial Neoplasia, Anal Cancer
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell…
- Conditions
- Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus
- Trial name
- NCT03947775
- Testing
- 9-valent HPV vaccination
- Where
- 4 sites in Canada
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vaginal Flora Imbalance, ASC-US
"Lactobacillus Crispatus M247, LSIL and Microbiota"
Patients affected by ASC-US/ low-grade HPV cervical lesions will be randomly assigned to treatment arm vs control arm. The treatment arm will include the characterization of the vaginal microbiota at enrollment (T0), 4 months of…
- Conditions
- Vaginal Flora Imbalance, ASC-US, LSIL, HPV Infection
- Trial name
- NCT05808816
- Testing
- Lactobacillus Crispatus M247
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) when administered concomitantly or…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02993757
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
- Where
- 5 sites in Malaysia
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cervical Cancer
Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer
Cervical cancer is the fourth most common cancer type among women worldwide and ranks ninth in Turkey, making it the second most common gynecological cancer.
- Trial name
- NCT06705309
- Testing
- Web-Based Education
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
HPV 16 Infection
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.
- Trial name
- NCT00365378
- Testing
- Comparator: HPV 16 L1 Vaccine
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC